All In MedTech

FDA Clearance Tracker · P120012

ABBOTT REALTIME HCV GENOTYPE II, ABBOTT REALTIME HCV GENOTYPE II CONTROL KIT, URACIL-N-GLYCOSYLASE (UNG)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jun 20, 2013 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

The decision

FDA number
P120012
Device name
ABBOTT REALTIME HCV GENOTYPE II, ABBOTT REALTIME HCV GENOTYPE II CONTROL KIT, URACIL-N-GLYCOSYLASE (UNG)
Applicant location
Des Plaines, IL
Received
Jul 12, 2012
Decided
Jun 20, 2013
Decision
Approved (reclassified)
Supplements
18 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 866.3170

Every decision under product code OBF

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE ABBOTT REALTIME HCV GENOTYPE II, ABBOTT REALTIME HCV GENOTYPE II CONTROL KIT, AND URACIL-GLYCOSYLASE(UNG). THIS DEVICE IS INDICATED FOR: ABBOTT REALTIME HCV GENOTYPE IITHE ABBOTT REALTIME HCV GENOTYPE II IS AN IN VITRO REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR) ASSAY FOR USE WITH THE ABBOTT MSAMPLE PREPARATION SYSTEM REAGENTS AND WITH THE ABBOTT M2000SP AND M2000RT INSTRUMENTS FOR THE QUALITATIVE IDENTIFICATION OFHEPATITIS C VIRUS (HCV) GENOTYPES 1, 1A, 1B, AND 2 - 5 IN PLASMA OR SERUM FROM INDIVIDUALS CHRONICALLY INFECTED WITH HCV.THE ABBOTT REALTIME HCV GENOTYPE II IS INTENDED FOR USE AS AN AID IN THE MANAGEMENT OF HCV-INFECTED INDIVIDUALS AND IN GUIDING THE SELECTION OF THERAPEUTIC TREATMENT INDICATED FOR THE ABOVE LISTED GENOTYPES. THE ASSAY IS INTENDED FOR USE ON PATIENTS WHO ARE CHRONICALLY INFECTED WITH HCV, ARE BEING CONSIDERED FOR ANTIVIRAL TREATMENT, AND ARE POSITIVE FOR HCV RNA. THE ABBOTT REALTIME HCV GENOTYPE II ASSAY IS NOT FOR SCREENING BLOOD, PLASMA, SERUM OR TISSUE DONORS FOR HCV. ABBOTT REALTIME HCV GENOTYPE II CONTROL KITTHE ABBOTT REALTIME HCV GENOTYPE II CONTROLS ARE USED TO ESTABLISH RUN VALIDITY OF THE ABBOTT REALTIME HCV GENOTYPE II ASSAY WHEN USED FOR DETERMINING THE GENOTYPE(S) OF HEPATITIS C VIRUS (HCV) IN PLASMA OR SERUM FROM INDIVIDUALS CHRONICALLY INFECTED WITH HCV. URACIL-N-GLYCOSYLASE (UNG) THE URACIL-N-GLYCOSYLASE (UNG) PROCEDURE IS TO BE USED IN CONJUNCTION WITH ABBOTT REALTIME HCV GENOTYPE II ASSAY AS AN OPTIONAL CONTAMINATION CONTROL FOR CUSTOMER LABORATORIES THAT ARE CURRENTLY USING OR HAVE PREVIOUSLY USED AMPLIFICATION TECHNOLOGIES THATINCORPORATE URACIL INTO THE AMPLIFICATION PRODUCT.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code OBF (Assay, genotyping, hepatitis c virus).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Abbott Molecular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.